Former Bristol Myers Squibb and Celgene executive to strengthen the Fund’s impact strategy and fuel transformative investments across innovative modalities BOSTON, Jan. 21, 2026 /PRNewswire/ — The T1D Fund: A Breakthrough …
Type 1